Click here to sign in with or
Forget Password?
Learn more
share this!
10
1
Share
Email
November 15, 2022
by Dr. Greg Carney, University of British Columbia
A study from the Therapeutics Initiative at the University of British Columbia investigated diabetes treatment patterns in British Columbia over the last two decades. The study, published in BMJ Open Diabetes Research & Care, highlights the increasingly complex treatment choices facing physicians and patients with type-2 diabetes and uncovered some startling trends.
A real-world study of over 300,000 adult participants treated for type 2 diabetes over the last 20 years found prescribing patterns that run contrary to treatment guideline recommendations. The use of metformin monotherapy, recommended as first line treatment in most patients, has declined by 17% over the last 10 years. The study also found that initial treatment has intensified, with rates of combination therapy more than doubling over the study period.
The study also found a decreasing trend in baseline blood glucose levels for newly treated patients over the last decade. Lead author Dr. Greg Carney says, “While we recognize guidelines recommend a patient-centered treatment approach, the trend towards treatment intensification, particularly among those with well-controlled blood glucose, is cause for concern. Overtreatment can put patients at increased risk of potential harms such as hypoglycemia.”
The availability of new blood glucose lowering medications provides physicians with numerous treatment options. Prescribing decisions are further complicated by government reimbursement policies and evolving guideline recommendations. The researchers hope their study’s findings will highlight the need for continued knowledge translation and quality improvement aimed at improving diabetes treatment.
The study included 362,391 participants newly treated with a blood glucose lowering medication between 2001 and 2020. The proportion of patients who received metformin monotherapy as first-line treatment reached a maximum of 90% in 2009, decreasing to 73% in 2020. The proportion of patients starting two-drug combinations nearly doubled from 3.3% to 6.4%. Sulfonylureas were the preferred class of second-line agents over the course of the study period.
Explore further
Facebook
Twitter
Email
Feedback to editors
2 hours ago
0
Nov 14, 2022
0
Nov 14, 2022
0
Nov 10, 2022
0
Nov 10, 2022
0
43 minutes ago
43 minutes ago
50 minutes ago
56 minutes ago
1 hour ago
1 hour ago
1 hour ago
1 hour ago
2 hours ago
2 hours ago
Jan 24, 2018
Sep 01, 2020
Jul 06, 2021
Sep 15, 2022
Sep 05, 2018
Sep 21, 2022
1 hour ago
4 hours ago
2 hours ago
18 hours ago
Nov 15, 2022
Nov 15, 2022
Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use our contact form. For general feedback, use the public comments section below (please adhere to guidelines).
Please select the most appropriate category to facilitate processing of your request
Thank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.
Your email address is used only to let the recipient know who sent the email. Neither your address nor the recipient’s address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.
Get weekly and/or daily updates delivered to your inbox. You can unsubscribe at any time and we’ll never share your details to third parties.
More information Privacy policy
Daily science news on research developments and the latest scientific innovations
The latest engineering, electronics and technology advances
The most comprehensive sci-tech news coverage on the web
This site uses cookies to assist with navigation, analyse your use of our services, collect data for ads personalisation and provide content from third parties. By using our site, you acknowledge that you have read and understand our Privacy Policy and Terms of Use.